Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Piccart, M.
Right arrow Articles by Pritchard, K. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piccart, M.
Right arrow Articles by Pritchard, K. I.
Related Collections
Right arrow 2003 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1017-1025, 2003
© 2003 European Society for Medical Oncology

Review Article

Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer

M. Piccart1,+, L. M. Parker2 and K. I. Pritchard3

1 Jules Bordet Institute, Brussels, Belgium; 2 Dana-Farber Cancer Institute, Boston, MA, USA; 3 Toronto-Sunnybrook Regional Cancer Centre, Toronto, Canada

Received 16 August 2002; revised 3 January 2003; accepted 25 February 2003

Abstract

Background:

Advanced breast cancer is largely incurable and current treatment modalities are aimed towards restricting tumour growth, prolonging survival, palliating symptoms and maintaining quality of life (QoL). The development of breast cancer is strongly influenced by endogenous oestrogens (and other growth factors), leading to a strong focus on the development of antioestrogenic compounds for the treatment of hormone-sensitive advanced disease.

Design:

This is a review of current endocrine therapies available for postmenopausal women with advanced breast cancer, examining the likely impact of newer agents on treatment strategies.

Results:

In postmenopausal women, current treatment options include tamoxifen, aromatase inhibitors (AIs) and megestrol acetate. Fulvestrant (‘Faslodex’) is a new, well-tolerated, oestrogen receptor antagonist that has no known agonist effect and is at least as effective as the AI anastrozole for the treatment of postmenopausal patients with metastatic or advanced breast cancer who have progressed on prior endocrine therapy. Fulvestrant maintains QoL throughout successful treatment.

Conclusions:

Fulvestrant represents a new treatment option for postmenopausal women with advanced disease. New agents that appear to lack cross-resistance with existing treatments may be used to extend the time period during which endocrine therapy may be employed before the need for cytotoxic chemotherapy.

Key words: advanced breast cancer, estrogen receptor downregulation, ‘Faslodex’, fulvestrant, postmenopausal, sequencing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Zoubir, M. C. Mathieu, C. Mazouni, C. Liedtke, L. Corley, S. Geha, J. Bouaziz, M. Spielmann, F. Drusche, W. F. Symmans, et al.
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy
Ann. Onc., August 1, 2008; 19(8): 1402 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.